Syntropac 250mcg Injection

Syntropac 250 mcg Injection contains tetracosactide, a synthetic analogue of adrenocorticotropic hormone (ACTH). It stimulates the adrenal cortex to produce corticosteroid hormones, including cortisol, helping healthcare professionals evaluate adrenal gland function.

Syntropac is used as a diagnostic aid when investigating suspected adrenal insufficiency, commonly through an ACTH stimulation test. Cortisol levels are measured before and after administration according to the prescribed diagnostic protocol.

Syntropac contains the same active ingredient as Synacthen 250 mcg injection and may be considered an alternative product where appropriately authorized. However, generic status, interchangeability and market availability must be confirmed for the specific product and destination country.

Product Information

Product Name

Syntropac Injection

Active Ingredient

Tetracosactide

Strength

250 mcg per 1 mL ampoule

Concentration

250 mcg/mL

Dosage Form

Sterile solution for injection

Drug Class

Synthetic ACTH analogue

Therapeutic Category

Diagnostic endocrine medicine

Primary Indication

Investigation of suspected adrenal insufficiency

Route of Administration

As specified in the applicable product information and diagnostic protocol

Pack Size

Confirm available packaging

Manufacturer/Marketer

Verify the current product label

Prescription Requirement

Subject to local regulations

Syntropac vs. Synacthen 250 mcg Injection

Syntropac and Synacthen 250 mcg ampoules contain tetracosactide, a synthetic ACTH analogue used in diagnostic assessment of adrenal function.

• Syntropac: A tetracosactide injection marketed under the Syntropac brand.
• Synacthen: A reference brand of tetracosactide injection.
• Active Ingredient: Tetracosactide.
• Strength: Verify that both products contain 250 mcg per 1 mL ampoule.
• Regulatory Status: Approval, generic designation and interchangeability depend on the country and the specific product authorization.

The same active ingredient and strength do not independently establish legal generic substitution. Confirm the manufacturer's details, formulation, official product information and regulatory status before listing or supplying Syntropac as a generic equivalent.

Ordering and Availability

For Syntropac 250 mcg Injection pricing, ampoule sizes and availability, contact the supplier to confirm the exact product, manufacturer, packaging and current stock.

Product authorization, prescription requirements and import eligibility vary by country. Verify local requirements and any necessary storage or cold-chain arrangements before ordering.

Syntropac 250 mcg Injection may be used by healthcare professionals for:

• Adrenal Function Assessment: Helps evaluate whether the adrenal glands respond appropriately to ACTH stimulation.
• Investigation of Adrenal Insufficiency: Supports the diagnostic assessment of suspected inadequate adrenal hormone production.
• Cortisol Response Testing: Stimulates cortisol production so that blood samples can be assessed at specified intervals.

Test results must be interpreted by a qualified healthcare professional alongside the patient's medical history, laboratory findings and applicable diagnostic criteria.

Syntropac 250 mcg Injection must be administered by a qualified healthcare professional according to the approved product instructions and the applicable clinical protocol.

A commonly used short ACTH stimulation test involves a single 250 mcg dose, with cortisol measurements taken before administration and at specified intervals afterward. The exact administration route, timing of blood samples and interpretation criteria should follow the local diagnostic protocol.

Do not self-administer this medicine or use it for repeated treatment without specialist direction. Confirm the exact product formulation and administration instructions before use.

Storage Instructions

Store Syntropac according to the manufacturer's instructions on the actual product packaging and leaflet. Verify the required temperature range, protection from light and expiry date before use.

If refrigerated storage or cold-chain transport is specified, those conditions must be maintained during storage and shipping. Do not use damaged, expired or improperly stored ampoules.

Possible adverse effects include:

• Injection-site discomfort
• Nausea or vomiting
• Flushing or feeling unwell
• Changes in blood pressure or heart rate
• Hypersensitivity reactions

Serious allergic reactions, including anaphylaxis, may occur. Administration should take place in a suitable clinical setting where the patient can be observed and emergency treatment is available.

Seek immediate medical assistance for difficulty breathing, swelling of the face or throat, widespread hives, collapse or other signs of a severe allergic reaction.

Before administration, the healthcare professional should review the patient's medical history, previous reactions to ACTH preparations and relevant current medicines.

Important precautions include:

• Hypersensitivity: Do not use in patients with a known allergy to tetracosactide, ACTH preparations or relevant product ingredients.
• History of allergic reactions: Particular caution is necessary in patients with asthma or other allergic conditions because of the risk of serious hypersensitivity.
• Diagnostic interpretation: Certain medicines and clinical conditions can affect cortisol measurements. The clinician should review potential influences on test results.
• Clinical monitoring: Administration must occur where serious adverse reactions can be promptly recognized and treated.
• Product identification: Confirm that the product is the intended short-acting tetracosactide injection and not a depot formulation.

Refer to the exact product leaflet for all contraindications, warnings and precautions.